Hereditary insulin-deficient diabetes mellitus occurs in certain sublines of nonobese Chinese hamsters. Several characteristics of this syndrome are similar to those seen in insulin-deficient human diabetics. Therefore, to characterize pancreatic islet function, dynamic insulin and glucagon release from normal and nonketotic diabetic hamster pancreases in response to glucose (300 mg/100 ml) and theophylline (10 mM), infused singly and together, was studied in vitro.
20-min glucose infusions of normal hamster pancreases caused biphasic insulin release, consisting of a rapid first peak and a gradually rising second phase, similar to that reported for man in vivo. Both phases were significantly reduced in the diabetic pancreases. Theophylline alone stimulated similar nonphasic insulin release in both the normal and the diabetic pancreases. Glucose and theophylline together caused greater insulin release than either stimulant alone in both normals and diabetics; however, the diabetic response was still subnormal.
Glucose suppressed glucagon release from normal pancreases; suppression was significantly impaired in diabetics. Theophylline stimulated nonphasic glucagon release in both the normals and diabetics. Glucose partially suppressed the theophylline-stimulated release in both groups.
Insulin/glucagon molar ratios of the diabetics were consistently subnormal, although individual hormone levels often overlapped into the normal range.
INTRODUCTION
Overt diabetes mellitus in nonobese humans is generally characterized by a diminished insulin response to glucose (1) . However, impaired insulin secretion may not be the only factor responsible for the abnormal glucose metabolism. Fasting hyperglucagonemia (2, 3) , lack of suppression of plasma glucagon by glucose (4, 5) , and excessive glucagon responses to amino acids (2, 6, 7) have been reported to occur in diabetics. These observations suggest that abnormal pancreatic alpha-cell function may also be involved. The cause of these abnormalities and their interrelationship is unclear, since investigations have been hindered by clinical heterogeneity, uncertainties introduced by-therapeutic intervention, and the lack of an appropriate animal model.
In 1959, Yerganian and Meier (8) reported the occurrence of spontaneous diabetes among certain inbred sublines of Chinese hamsters. The syndrome is, at least in part, genetically determined, and its spectrum ranges in severity from intermittent glucosuria to ketoacidosis. Although prediabetic hamsters are hyperphagic (and may be mildly obese) when young (9, 10) , the adults are the only spontaneously diabetic laboratory animals that are not obese (11, 12) . They develop neuropathy
The Journal of Clinical Investigation Volume 53 June 1974 1637-1646 1637 (13) , nephropathy (14) , retinopathy (15) , and abnormal lipid metabolism (16) , closely resembling the complications of human diabetes. Moreover, the impaired insulin responses to glucose (16) (17) (18) , diminished pancreatic insulin content (16, 19, 20) , and abnormal islet morphology (21) reported in these animals parallel features found in lean human diabetics of both maturityonset and juvenile-onset types. Although no animal may be identical to the human, the diabetic Chinese hamster may be a particularly useful model for the nonobese insulin-deficient human diabetic.
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METHODS Animals
talsis from this pump (0.5-1.0 mm Hg) is negligible. Arterial/venous oxygen tension was measured during several perfusions, and oxygen uptake was calculated; uptake (0.06 ml 02/g dry wt/min) was constant and similar to that of the per-fused rat pancreas (25) . Oxygen uptake, gastric juice secretion, and duodenal peristalsis remained constant throughout the perfusions. Concentrated glucose was added via sidearm syringe in buffer at a rate of 0.1 ml buffer/min. Since anhydrous theophylline was not readily soluble in small amounts of perfusate, a parallel pumping system was used to supply perfusate containing 10 mM theophylline dissolved in buffer. The portal vein effluent, collected in an ice bath at 1-min intervals by automatic fraction collector, was stored until assay (within 4 wk) at -200C. After the perfusion, the pancreas was dissected free from the duodenum and other tissues, weighed, and frozen until extraction. Experimental design. After approximately 15 min equilibration and collection of two zero-time samples (min -1 and 0), the pancreases from a total of 11 normal and 17 diabetic hamsters were exposed to a 20-min glucose infusion (300 mg/100 ml; 16.7 mM). To obtain more information with the limited number of animals available, some of the pancreases were subsequently perfused with additional stimuli during which insulin (10 normals, 9 diabetics) and glucagon 2 (6 normals, 5 diabetics) responses were measured (Table II) . 10-min rest periods, found adequate in similar perfusions of rat pancreases, were interposed between stimuli to minimize the effects one stimulation might have on the next. In these experiments, pan-'Assay of glucagon became available after normals (nos. [1] [2] [3] [4] [5] and diabetics (nos. 1-12) had already been studied. creases were exposed to the following agents: (a) glucose, 300 mg/100 ml (16.7 mM), 20 min, followed by (b) theophylline, 10 mM (180 mg/100 ml), 20 
RESULTS
Insulin and glucagon responses to glucose (300 mg/100 ml) ( Fig. 1 and Table II) Insulin. Basal (unstimulated) secretion was similar in all animals. The normal hamster pancreases responded 1640 Frankel, Gerich, Hagura, Fanska, Gerritsen, and Grodsky to continuous glucose infusion in a biphasic manner: the first phase consisted of a spikelike release that reached maximal levels within 4 min; this was followed by a nadir and the second phase, a more prolonged response. The first peak, or phase, was taken as the area under the curve during the first 7 min of stimulation, and the second phase as the area thereafter. Despite a wide overlap of normal and diabetic responses, the mean (±SE) diabetic first and second phases of insulin release were significantly reduced to a similar extent (54±15% and 50±13% of normal, respectively). In both individual normal and diabetic animals, the amount of insulin released in the first phase was positively correlated to second phase release (r = 0.79, P < 0.005; r = 0.94, P < 0.0005, respectively).
Other studies from this laboratory indicate that both phases begin simultaneously and overlap during the first few minutes of stimulation (31) . In many cases, simply separating the phases at the nadir overestimates the first phase. Theoretically, it is more accurate to extrapolate the second phase to zero and subtract the overlap from the first phase (32) ; however, extrapolation is often difficult and arbitrary. With this approach, applied to the mean data in Fig. 1 , inhibition of first and second phases was 53 and 49% of normal, respectively.
Mean pancreatic insulin content after perfusion of the diabetic pancreases (0.373±0.067 U/g) was significantly less than that in the normals (1.054±0.240 U/g, P < 0.01) (Table I) Insulin secretion refers to total release during a 20-min glucose infusion (300 mg/100 ml) from the individual pancreases summarized in Fig. 1 . Glucose values were from blood collected from animals during laparotomy immediately before pancreatic removal (Table I) . Glucose determinations were performed in 9 of 11 normal and 11 of the 17 diabetic animals. (0) and diabetic (0) Chinese hamster pancreases to 20-min infusions of glucose (300 mg/100 ml), theophylline (10 mM), and glucose (300 mg/100 ml) plus theophylline (10 mM). Insulin measurements from 10 normals (nos. 2-11) and 9 diabetics (nos. 9-17) ; glucagon measurements from 6 normals (nos. 6-11)-and 5 diabetics (nos. [13] [14] [15] [16] [17] . (*) P < 0.05.
cose at laparotomy, (Fig. 2) , and duration of diabetes did not correlate with the amount of insulin released in response to glucose in either normals or diabetics. Impaired insulin release in the diabetics was correlated with mean urine sugar, measured every 2 wk during life (r = 0.441, P < 0.05). Glucagon. Basal secretion was similar in both normal and diabetic groups. Glucose suppressed glucagon secretion in normals within 5 min; there was maximum suppression to a mean of less than 10% of zero-time by 10 min. In the diabetics, glucagon release was suppressed to only 56% during the same period. Total glucagon secretion during this interval (Table II) was significantly greater (P < 0.02) in the diabetics than in the normals.
After the glucose infusion, both normal and diabetic glucagon levels did not return to the preglucose values, but established a new lower basal level (Fig. 3 ).
Insulin and glucagon responses to theophylline (10 mM) ( Fig. 3 6ean (±SE) insulin and glucagon responses of normal (0) and diabetic (0) Chinese hamster pancreases stimulated by theophylline alone (10 mM) without any prior stimulus. The pancreases were obtained from similar animals and were involved in other studies to be reported in detail elsewhere.
Comparison of total insulin and glucagon release and insulin/glucagon molar ratios Total insulin and glucagon released (area under the curve for 0-80 min) from the individual pancreases are summarized in Fig. 5 . Two diabetics had total insulin responses within the range observed for the normal animals but had excessive glucagon release; two diabetics had glucagon responses within the range of the normals but had lower insulin levels; no diabetic had both normal insulin and normal glucagon responses. This resulted in the diabetics consistently having decreased insulin/glucagon molar ratios for the total 80-min interval (Fig. 6) . There was no evidence that those diabetics with the highest insulin release had the lowest glucagon release. Rather, those diabetics with the highest insulin release also had the highest glucagon release (Fig. 5) .
Influence of subline on insulin release A total of four normal and seven diabetic Chinese hamster sublines were "sampled"' during these experiments (Table I) . Although too few animals were studied to give a large n in each subline, several sublines showed large variations in hormone release from one animal to the next, while one particular sublime, X, consistently showed poorer insulin release in response to glucose. There was no correlation in the diabetics between the mean insulin response of the subline and the number of generations that subline had been inbred, blood glucose at laparotomy, or mean biweekly urine sugar. ulus, caused similar glucagon release from six diabetic and five normal pancreases (Fig. 4) .
Insulin and glucagon responses to glucose (300 mg/100 ml) plus theophylline (10 mM) ( Fig. 3 and Table II) Insulin. The insulin response of the normals was biphasic and significantly greater than during either glucose or theophylline alone. The response of the diabetics to this combined stimulation was also greater than to either stimulant alone, total insulin release being quantitatively similar to that in the normals stimulated by glucose alone. However, the diabetics' response was still significantly less (P < 0.01) than the normals' response to this same combined stimulation.
Glucagon. In the normals and diabetics, glucose plus theophylline tended to cause less glucagon release than did theophylline alone. The diabetics' glucagon responses to glucose plus theophylline were greater than the normals'; however, the statistical significance of this difference (P = 0.08) was not as definitive as when the pancreases were exposed to glucose alone (P = 0.02). 
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Frankel, Gerich, Hagura, Fanska, Gerritsen, and Grodsky (35) suggested that early insulin release may be preferentially diminished in human diabetics, but they did not study second phase release. Cerasi and Luft (36) recently found that both phases of insulin release are significantly impaired in human diabetics and suggested that the mechanisms governing both phases of insulin responses to glucose are similar. Evidence for a common glucose signal for both phases is derived from the observation that in normal rats (31) and man (36) the glucose Km for the first and second phases are the same. Both phases of insulin release were impaired with equal frequency and to a similar extent in our diabetic hamsters. These findings are thus consistent with the concept of an early defect of glucose action, possibly involving a glucose receptor (36, 37) rather than a preferential defect in some mechanism underlying one of the phases. This defect appears relatively specific for glucose, since theophylline both stimulated insulin release and augmented glucose-stimulated insulin release similarly in both normals and diabetics. Although total pancreatic insulin was less in the diabetics, this did not appear to be a major cause of their decreased glucosestimulated insulin release, since response to theophylline was normal and since there was no correlation between insulin release and stored insulin within either the normal or diabetic groups. Our findings are also in accord with those in man by Robertson and Porte (37) , who found that, despite abnormal insulin responses to glucose, diabetics' insulin -responses to isoproterenol were normal, suggesting a defect specific for glucosemediated insulin secretion.
Elevated fasting glucagon levels have been reported in human diabetics with (3, 6, 33) and without (38) concomitant hyperglycemia. From the diabetic hamster pancreases, basal glucagon secretion (at zero glucose) was similar to normals. These "basal" data probably are The present studies demonstrate that theophylline not only increases insulin secretion but is also a stimulator of glucagon release, consistent with the observations of Jarrousse, Ranqon, Rosselin, and Freychet (40) using the newborn rat pancreas. Thus, both the pancreatic alpha and beta cell may be positively modulated by increased cyclic AMP-a conclusion also recently suggested for man (41) .
The similar responses to theophylline in normal and diabetic pancreases suggest that the mechanism through which theophylline acts (presumably through elevating intracellular cyclic AMP) is relatively intact in both the beta and alpha cell of the genetically diabetic hamster. Our results are similar to Cerasi and Luft's finding (34) that aminophylline could partially "normalize" some human prediabetics' insulin responses to glucose. Our experiments, however, showed that theophylline augmented, but did not quantitatively normalize, the glucose-stimulated insulin release in the diabetics.
Certain diabetic pancreases had total insulin release within the range of the normals but excessive glucagon secretion; others had subnormal insulin release with normal glucagon secretion. None had responses in the range of the normals of both hormones. This relationship could be expressed as a significantly (P <0.02) decreased insulin/glucagon ratio. Thus, in agreement with Unger (42), the insulin/glucagon molar ratio, although not a significant number in itself, since it suggests an unproven linear relationship, may nevertheless represent the status of pancreatic responses more accurately than measurement of the level of either hormone alone. Moreover, the insulin/glucagon molar ratio may have clinical applicability by demonstrating in a single individual an inappropriate level of insulin for a given glucagon level and vice versa.
Diabetes is often attributed to genetics when identical twins both develop the disease and to environment when they do not. There are several sublines of Chinese hamsters which have been brother-sister inbred for 10 or more generations and thus have, theoretically, more than 90% genetic homozygosity (43) . Nevertheless, these animals are not 90% phenotypically identical with regard to severity of their diabetes, suggesting a contribution by environmental factors. Despite our careful selection for nonketotic diabetics of similar severity, there was a wide overlap of the individual normal and diabetic insulin responses to glucose. This variation in insulin release was noted both between and within sublines, suggesting what is often suspected of human diabetes mellitus-that we may be dealing with several different genetic contributions to the diabetic disease. The fact that one subline with consistently low insulin (X) was no more diabeic than the others supports the probability that impaired beta-cell function is not solely responsible for genetic diabetes. The recent series represents the first attempt to examine hormone secretion from different sublines, but more animals must be studied in each diabetic hamster subline before definite conclusions can be drawn.
In conclusion, the diabetic Chinese hamster may be a valuable experimental model for studying the metabolic abnormalities of a genetic diabetic syndrome not easily measured in man in vivo. In the diabetic hamster, both phases of insulin release in response to glucose were reduced; insulin and glucagon responses to theophylline were normal; theophylline enhanced but did not completely normalize glucose-stimulated insulin release; inhibition of glucagon secretion by glucose was impaired and did not appear to be correlated with insulin deficiency; and insulin/glucagon molar ratios were reduced despite occasional normal levels of one or the other hormone. These results suggest that both alpha and beta cells of the diabetic pancreas may have a relatively specific impaired sensitivity to glucose.
